Abituzumab

01/01/2017 - "DI17E6 inhibited migration and invasion of prostate cancer cells. "
01/01/2017 - "To evaluate this, prostate cancer cells were treated with DI17E6 and its effects on proliferation, apoptosis, cell-cycle, adhesion, detachment, migration, invasion and phosphorylation of downstream targets, including FAK, Akt, and ERK, were determined. "
01/01/2016 - "Although PFS was not significantly extended, abituzumab appears to have specific activity in prostate cancer-associated bone lesions that warrants further investigation. "
01/01/2017 - "These results indicate that inhibition of integrin αV with DI17E6 inhibits several prometastatic phenotypes of prostate cancer cells and therefore provide a rationale for further evaluation of DI17E6 for diminishing prostate cancer progression.Implications"
01/01/2017 - "Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression."

01/01/2021 - "STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease."
01/01/2021 - "To investigate the effects of abituzumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD). "

01/01/2015 - "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial."

01/01/2021 - "STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease."
01/01/2021 - "To investigate the effects of abituzumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD). "

05/01/2014 - "A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy."